ri:val Knowledge Base
Deal Analysis with ri:val: CellGenesys - Takeda
Deal Analysis with ri:val: Adnexus - BMS
Deal Analysis with ri:val: Ardea - Bayer
Deal Analysis with ri:val: Plexxikon - Roche
Deal Analysis with ri:val: Celldex - Pfizer
Deal Analysis with ri:val: KyowaKirin - Amgen
Deal Structuring with ri:val
Multivariate analysis in ri:val
Sensitivity analysis in ri:val
A statistical view on success rates
Phase 2a and 2b transition probabilities
Why drug prices must be high
Biotech Success Rates: NCEs vs. Biologicals
Biotech Success Rates: Going the Wrong Way
Avance Survey on Financial Crisis and Impact on Pharma and Biotech
The US$ 1 bio drug. A fairytale
How to Apply Success Rates to Valuation
Evolution of valuation
Sensitivities in valuation
High finance in biotech?
Early-stage project valuation myths
NPV vs. rNPV
Survey on discount rates in biotech
Should we discount by project or by company?
Should we discount by project or by company? (continued)
Black's discounting rule
Black's discounting rule (Excel)
Real Options: Dos and Don'ts
Discount Rates in Pharma and Biotech
Black Scholes for Real Options
Early Stage Valuation
How to determine fair option agreement terms?
Early-Stage Licensing: How to Determine Sublicensing Terms
Discovery & Preclinical Deals. What's realistic?
Reading Deals - How to Interpret License Deals
Co-Development Deals - How to Determine a fair Value Share?
Multi-Indication Deals - How to Value them.
Why are royalties up-tiered?
How Biotech Stocks Behave
Staged Take-Overs: New Structure on the Rise
Non-Dilutive Financing Alternatives
Biotech Taxes - Effects on Valuation
P/E Ratio for Biotech Valuation
Arbitrary Terminal Value
To take advantage of ri:val software or to learn how ri:val can benefit you, contact us by phone or email us at email@example.com
Get on the ri:val mailing list and sign up for our email newsletter to discover what's new about ri:val and topical industry information.